Focal Segmental Glomerulosclerosis Global Market Report 2025

The focal segmental glomerulosclerosis market size has grown strongly in recent years. It will grow from $1.46 billion in 2024 to $1.57 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth during the historic period can be attributed to the rising prevalence of chronic kidney diseases, increased awareness of kidney disorders, a growing incidence of end-stage renal disease, higher investments in research and development, and an expanding geriatric population.

The focal segmental glomerusclerosis market size is expected to see strong growth in the next few years. It will grow to $2.09 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth projected for the forecast period can be attributed to an increasing number of clinical trials, improvements in healthcare infrastructure, rising demand for personalized medicine, greater availability and accessibility of immunosuppressive drugs, and a growing need for tailored therapeutic interventions. Key trends expected during this period include advancements in genetic research, the integration of precision medicine, technological innovations in diagnostic tools, the development of new formulations of immunosuppressive drugs, and progress in biomarker identification.

The increasing prevalence of kidney diseases is expected to drive the growth of the focal segmental glomerulosclerosis (FSGS) market in the coming years. Kidney diseases are conditions that compromise the kidneys’ structure and function, impairing their ability to filter waste, regulate fluids, and maintain essential physiological processes. A major contributor to this rise is diabetes, as prolonged high blood sugar levels can damage the kidneys’ filtering units, leading to diabetic nephropathy. FSGS, characterized by progressive scarring of the glomeruli, is a key indicator and focus for the diagnosis, understanding, and treatment of chronic kidney diseases. For example, in December 2024, the Australian Institute of Health and Welfare reported that mortality rates from chronic kidney disease (CKD) increased year-on-year in both 2021 and 2022, with rises of 4.2% and 6.2%, respectively. Thus, the growing prevalence of kidney diseases is contributing to the expansion of the FSGS market.

Major companies in the focal segmental glomerulosclerosis (FSGS) market are prioritizing the development of innovative therapies, such as non-immunosuppressive oral medications, to enhance patient outcomes and minimize treatment-related side effects. These medications are taken orally and treat the condition without compromising the immune system, directly targeting kidney damage and avoiding the immune-related complications commonly associated with traditional therapies. For example, in May 2025, Travere Therapeutics Inc., a U.S.-based biopharmaceutical company, received traditional approval from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for FILSPARI (sparsentan) for the treatment of FSGS. FILSPARI is a first-in-class therapy that functions by simultaneously blocking the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R). This dual-action mechanism significantly reduces proteinuria in diseases like FSGS and IgA nephropathy, offering enhanced kidney protection and maintaining a favorable safety profile compared to existing treatments.

In August 2023, Novartis AG, a Switzerland-based pharmaceutical company, acquired Chinook Therapeutics Inc. for $3.5 billion. This acquisition is intended to bolster Novartis’s position in the treatment of rare kidney diseases by enhancing its innovative pipeline with late-stage therapies targeting IgA nephropathy. Chinook Therapeutics Inc., a U.S.-based biotechnology company, is actively engaged in developing therapies for conditions such as focal segmental glomerulosclerosis (FSGS).

Major players in the focal segmental glomerulosclerosis market are Pfizer Inc., Merck And Co. Inc., Sanofi S.A., Eli Lilly and Company, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Mallinckrodt ARD LLC, Kyowa Kirin Co. Ltd., Aurinia Pharmaceuticals Inc., Travere Therapeutics Inc., Eledon Pharmaceuticals Inc., ZyVersa Therapeutics Inc., Complexa Inc., Certa Therapeutics, Delta 4 GmbH, Dimerix Limited, Goldfinch Bio Inc., Oraxion Therapeutics Inc., and Variant Pharmaceuticals Inc.

North America was the largest region in the focal segmental glomerulosclerosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in focal segmental glomerulosclerosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the focal segmental glomerulosclerosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Focal segmental glomerulosclerosis (FSGS) is a rare kidney condition characterized by scarring (sclerosis) in portions of some glomeruli - the kidney’s filtering units - leading to proteinuria and progressive kidney damage. It is significant in clinical diagnosis and research focused on proteinuria-related kidney disorders and the development of targeted treatments to prevent kidney failure.

The two primary types of FSGS are primary focal segmental glomerulosclerosis and secondary focal segmental glomerulosclerosis. Primary FSGS is a kidney disease involving scarring in specific (focal) and partial (segmental) areas of some glomeruli, resulting in proteinuria and gradual kidney function decline without an identifiable secondary cause. Treatment approaches include drug therapy, dialysis, kidney transplantation, and other interventions. The main drug classes used are immunosuppressants, angiotensin inhibitors, and corticosteroids, administered through oral and parenteral routes. These treatments are provided in various care settings, including hospitals, homecare, specialty clinics, and other healthcare facilities.

The focal segmental glomerulosclerosis market research report is one of a series of new reports that cover focal segmental glomerulosclerosis market statistics, including the focal segmental glomerulosclerosis industry's global market size, regional shares, competitors with the focal segmental glomerulosclerosis market share, detailed focal segmental glomerulosclerosis market segments, market trends and opportunities, and any further data you may need to thrive in the focal segmental glomerulosclerosis market. This focal segmental glomerulosclerosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The focal segmental glomerulosclerosis market consists of revenues earned by entities by providing services such as diagnostic testing, dialysis services, kidney transplant services, supportive care services, and medical imaging. The market value includes the value of related goods sold by the service provider or included within the service offering. The focal segmental glomerulosclerosis market also includes sales of calcineurin inhibitors, mycophenolate mofetil, rituximab, sparsentan, and diuretics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.